BR0316170A - Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer - Google Patents
Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncerInfo
- Publication number
- BR0316170A BR0316170A BR0316170-6A BR0316170A BR0316170A BR 0316170 A BR0316170 A BR 0316170A BR 0316170 A BR0316170 A BR 0316170A BR 0316170 A BR0316170 A BR 0316170A
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- cancer
- prophylaxis
- pharmaceutical composition
- synergistic treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Control And Other Processes For Unpacking Of Materials (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
"COMBINAçãO, COMPOSIçãO FARMACêUTICA, USO DE UMA COMBINAçãO, E, MéTODO PARA A PROFILAXIA OU TRATAMENTO SINERGìSTICO DE CâNCER". A invenção refere-se a uma combinação compreendendo um inibidor de quinase de Src e o agente citotóxico gemcitabine, uma composição farmacêutica compreendendo uma combinação do tipo referido e seu uso no tratamento ou profilaxia de câncer, particularmente de câncer pancreático.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0226434.9A GB0226434D0 (en) | 2002-11-13 | 2002-11-13 | Combination product |
PCT/GB2003/004787 WO2004043472A1 (en) | 2002-11-13 | 2003-11-07 | Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0316170A true BR0316170A (pt) | 2005-09-27 |
Family
ID=9947715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0316170-6A BR0316170A (pt) | 2002-11-13 | 2003-11-07 | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20060142297A1 (pt) |
EP (1) | EP1562612B1 (pt) |
JP (1) | JP2006508953A (pt) |
KR (1) | KR20050074573A (pt) |
CN (1) | CN100467027C (pt) |
AT (1) | ATE456370T1 (pt) |
AU (1) | AU2003279456B2 (pt) |
BR (1) | BR0316170A (pt) |
CA (1) | CA2504666A1 (pt) |
DE (1) | DE60331162D1 (pt) |
ES (1) | ES2338109T3 (pt) |
GB (1) | GB0226434D0 (pt) |
NO (1) | NO20052312L (pt) |
NZ (1) | NZ539514A (pt) |
WO (1) | WO2004043472A1 (pt) |
ZA (1) | ZA200503805B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525324A (en) | 2000-10-20 | 2005-03-24 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
US7462623B2 (en) * | 2002-11-04 | 2008-12-09 | Astrazeneca Ab | Quinazoline derivatives as Src tyrosine kinase inhibitors |
US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
GB0412074D0 (en) | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
WO2006030826A1 (ja) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
GB0427697D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
CA2675736A1 (en) | 2007-01-19 | 2008-07-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
WO2012144463A1 (ja) | 2011-04-18 | 2012-10-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
TWI577671B (zh) | 2011-11-14 | 2017-04-11 | Sunshine Lake Pharma Co Ltd | Aminoquinazoline derivatives and salts thereof and methods of use thereof |
WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
TWI721954B (zh) | 2014-08-28 | 2021-03-21 | 日商衛材R&D企管股份有限公司 | 高純度喹啉衍生物及其生產方法 |
SI3263106T1 (sl) | 2015-02-25 | 2024-02-29 | Eisai R&D Management Co., Ltd. | Postopek zatiranja grenkobe derivata kinolina |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
US20170022576A1 (en) | 2015-03-18 | 2017-01-26 | The Regents Of The University Of California | Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents |
CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
US6469058B1 (en) * | 1998-09-25 | 2002-10-22 | Warner-Lambert Company | Chemotherapy of cancer with actyldinaline in combination with gemcitabine capecitabine or cisplatin |
DE60006541D1 (de) * | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
-
2002
- 2002-11-13 GB GBGB0226434.9A patent/GB0226434D0/en not_active Ceased
-
2003
- 2003-11-07 CN CNB2003801031384A patent/CN100467027C/zh not_active Expired - Fee Related
- 2003-11-07 CA CA002504666A patent/CA2504666A1/en not_active Abandoned
- 2003-11-07 US US10/534,721 patent/US20060142297A1/en not_active Abandoned
- 2003-11-07 AT AT03772404T patent/ATE456370T1/de not_active IP Right Cessation
- 2003-11-07 WO PCT/GB2003/004787 patent/WO2004043472A1/en active IP Right Grant
- 2003-11-07 DE DE60331162T patent/DE60331162D1/de not_active Expired - Lifetime
- 2003-11-07 NZ NZ539514A patent/NZ539514A/en unknown
- 2003-11-07 BR BR0316170-6A patent/BR0316170A/pt not_active IP Right Cessation
- 2003-11-07 EP EP03772404A patent/EP1562612B1/en not_active Expired - Lifetime
- 2003-11-07 ES ES03772404T patent/ES2338109T3/es not_active Expired - Lifetime
- 2003-11-07 AU AU2003279456A patent/AU2003279456B2/en not_active Ceased
- 2003-11-07 KR KR1020057008291A patent/KR20050074573A/ko not_active Application Discontinuation
- 2003-11-07 JP JP2004550784A patent/JP2006508953A/ja active Pending
-
2005
- 2005-05-11 ZA ZA200503805A patent/ZA200503805B/en unknown
- 2005-05-11 NO NO20052312A patent/NO20052312L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2504666A1 (en) | 2004-05-27 |
NO20052312L (no) | 2005-06-06 |
CN100467027C (zh) | 2009-03-11 |
JP2006508953A (ja) | 2006-03-16 |
US20060142297A1 (en) | 2006-06-29 |
EP1562612B1 (en) | 2010-01-27 |
CN1711094A (zh) | 2005-12-21 |
KR20050074573A (ko) | 2005-07-18 |
AU2003279456A1 (en) | 2004-06-03 |
ES2338109T3 (es) | 2010-05-04 |
ATE456370T1 (de) | 2010-02-15 |
GB0226434D0 (en) | 2002-12-18 |
ZA200503805B (en) | 2006-09-27 |
EP1562612A1 (en) | 2005-08-17 |
NZ539514A (en) | 2007-11-30 |
AU2003279456B2 (en) | 2007-05-17 |
DE60331162D1 (de) | 2010-03-18 |
WO2004043472A1 (en) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0316170A (pt) | Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer | |
SV2009003227A (es) | Composiciones de inhibidores de chk 1 ref. x-17672 | |
BRPI0517887A (pt) | combinações de inibidores de jaks | |
NO20060392L (no) | Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer | |
WO2004030627A3 (en) | Synergistic methods and compositions for treating cancer | |
BRPI0617165A2 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
BRPI0515721A (pt) | uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação | |
NO20034433L (no) | Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil | |
NO20050795L (no) | Forbindelser, blandinger og fremgangsmater for utnyttelse av samme | |
PA8493401A1 (es) | Uso de inhibidores de cyp2d6 en terapias de combinacion | |
BRPI0511475A (pt) | combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer | |
SE0202598D0 (sv) | Alpha-7 Nicotinic receptor agonists and statins in combination | |
CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
BRPI0718469A2 (pt) | Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto. | |
WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
PL1824504T3 (pl) | Kombinacja przeciwnowotworowa zawierająca vegf-trap i 5fu lub jedną z jego pochodnych | |
TW200730190A (en) | New combination to treat liver fibrosis | |
PT1282418E (pt) | Utilizacao de derivados pirazolo para o tratamento da infertilidade | |
HUP0401854A2 (hu) | COX-2 inhibitorokat és aszpirint tartalmazó kombinációk | |
MXPA05011213A (es) | Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia. | |
MX2007009914A (es) | Uso de agonistas selectivos para el receptor-beta de estrogeno para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion. | |
WO2007042465A3 (en) | Combinati0n of nilotinib with farnesyl transferase inhibitors | |
MX2023011759A (es) | Composicion farmaceutica para prevenir o tratar la enfermedad renal cronica que incluye el derivado de glucagon. | |
HUP0303589A2 (hu) | Egy taxán és egy ciklin-dependens kináz inhibitor kombinációja |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |